Kurma Partners - Acteur majeur de l'investissement dans la santé eu Europe

Crédit photo : Institut Pasteur

16/11/2017

Kurma Partners announces the successful IPO of Orphazyme.

Kurma Partners announces the successful IPO of Orphazyme, a leading company in rare diseases which raises €80M on Nasdaq Copenhagen [....]

contact@kurmapartners.com

Tél: +33 (0)1 84 86 08 61

24, rue Royale
75008 Paris
France